Immutep Limited (IMMP)
| Market Cap | 287.86M |
| Revenue (ttm) | 2.56M |
| Net Income (ttm) | -28.50M |
| Shares Out | 1.45B |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 72,991 |
| Open | 2.030 |
| Previous Close | 2.020 |
| Day's Range | 1.910 - 2.030 |
| 52-Week Range | 1.660 - 3.340 |
| Beta | 1.92 |
| Analysts | Buy |
| Price Target | 8.50 (+333.67%) |
| Earnings Date | Nov 26, 2024 |
About IMMP
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical ... [Read more]
Financial Performance
In 2024, Immutep's revenue was 3.84 million, an increase of 9.59% compared to the previous year's 3.51 million. Losses were -42.72 million, 7.07% more than in 2023.
Financial numbers in AUD Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for IMMP stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 333.67% from the latest price.
News
Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients
Positive results from phase 1 INSIGHT-003 study, using eftilagimod alpha in combination with KEYTRUDA and chemotherapy in treating first-line metastatic non-squamous NSCLC patients. Additional data fr...
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
On Thursday, Immutep Limited IMMP released data from the INSIGHT-003 Phase 1 trial of eftilagimod alpha (efti) in combination with Merck & Co Inc's MRK Keytruda (pembrolizumab) and chemotherapy for fi...
Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 m...
Immutep Quarterly Activities Report Q1 FY25
SYDNEY, AUSTRALIA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapie...
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
Media Release SYDNEY, AUSTRALIA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...
Immutep: Navigating The Bumps In The Road
Immutep Limited (IMMP) has shown underwhelming results in their TACTI-003 trial, raising questions about the efficacy of their lead drug, eftilagimod. Despite the disappointing data, IMMP has a strong...
Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
SYDNEY, AUSTRALIA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapi...
Immutep Quarterly Activities Report Q4 FY24
Media Release Entered into third and most important clinical trial collaboration and supply agreement to date with MSD to evaluate eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab)...
Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs
Immutep Limited achieved positive results in the phase 2b study, using efti + Keytruda for the treatment of patients with 1st-line head and neck squamous cell carcinoma; Both PD-L1 positive and negati...
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approa...
Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results
Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July) SYDNEY, AUSTRALIA, July 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinica...
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
Media Release SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...
Immutep successfully completes institutional placement and institutional component of entitlement offer
Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) (Immutep or the Company) is pleased to announce the successful completion of its instituti...
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
SYDNEY, AUSTRALIA, June 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapie...
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
Media Release Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxel Ongoing ...
Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial Four of six pat...
Immutep: Realizing The Expected Catalysts, With More To Come
Immutep Limited is focused on developing novel treatments targeting LAG3, an immune checkpoint, for various tumor types. The company's pipeline includes eftilagimod, which has shown promising response...
Immutep Quarterly Activities Report Q3 FY24
Media Release First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% overall response rate, including one patient r...
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Media Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9% respons...
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address ...
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
SYDNEY, AUSTRALIA, April 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapi...
Immutep Announces First Clinical Data from 90mg Dosing of Efti
SYDNEY, AUSTRALIA, March 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapi...
Immutep Quarterly Activities Report Q2 FY24
Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing P...
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
Media Release SYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...
Immutep: Upcoming Signals For 2024 (Maintain Buy)
Immutep Limited's lead molecule, eftilagimod, has shown signals of activity in lung cancer and has the potential to be a chemotherapy-free regimen with manageable toxicity. The company has received re...